Señales en vivo de GBT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 oct 2022 @ 16:00):

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD)...

Stats
Volumen de hoy	3.28M
Volumen promedio	0
Capitalización de mercado	0.00
EPS	$0 ( 2022-11-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-14.08
ATR14	$0.890 (1.30%)

Insider Trading

Date	Person	Action	Amount	type
2022-10-05	Perry Mark L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Patrick Deval L	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Morrison Scott W	Sell	5 600	Stock Option (Right to Buy)
2022-10-05	Thompson Alexis A.	Sell	3 600	Restricted Stock Units
2022-10-05	Yarno Wendy L	Sell	30 000	Stock Option (Right to Buy)

INSIDER POWER
-60.35
Last 100 transactions
Buy: 278 284 \| Sell: 1 075 911

Volumen Correlación

Largo: 0.35 (neutral)

Corto: 0.93 (very strong)

Signal:(77.112) Expect same movement, but be aware

Global Blood Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Global Blood Correlación - Moneda/Commodity

0.94
( very strong )

0.92
( very strong )

-0.79
( moderate negative )

0.83
( strong )

0.23
( neutral )

-0.61
( weak negative )

Global Blood Finanzas

Annual	2021
Ingresos:	$194.75M
Beneficio Bruto:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2021
Ingresos:	$194.75M
Beneficio Bruto:	$191.43M (98.30 %)
EPS:	$-4.82

FY	2020
Ingresos:	$123.80M
Beneficio Bruto:	$121.82M (98.40 %)
EPS:	$-4.04

FY	2019
Ingresos:	$2.11M
Beneficio Bruto:	$2.06M (97.72 %)
EPS:	$-4.57

Financial Reports:

No articles found.

Global Blood

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.